Diligence memo · auto-generated · as of July 2, 2026
Galecto, Inc.
Galecto, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Galecto, Inc. operates in Pharmaceuticals, based in Boston.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Galecto, Inc. has raised $428M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $285M on 2025-11-12.
Most recent recorded round closed around 2025-11-12.
Valuation (modeled)modeled
Provath models Galecto, Inc. at approximately $2.0B (range $1.4B–$2.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.27× the median modeled value of Series D+ Pharmaceuticals companies in 2025–2027 (7 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 35 months.
Last raise 8 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 4.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 99% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: DBV Technologies S.A., NovaBay Pharmaceuticals, Inc., Pelage Pharmaceuticals, Inc., Triana Biomedicines, Inc., Quoin Pharmaceuticals, Ltd..
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.